We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nalge Nunc to Market High-Content Screening Tool

By Biotechdaily staff writers
Posted on 02 Jun 2006
Nalge Nunc International Corporation (Rochester, NY, USA) has announced an agreement with Molecular Cytomics Inc. More...
(Boston, MA, USA), a biotechnology company that develops high content, cell-based technologies. The agreement provides global distribution rights to Nalge Nunc International for the sale and support of Molecular Cytomics' first product family, the Optical LiveCell array.

The products will be marketed under the brand name Nunc LiveCell array, and will consist of specialized microscope slides and kits with reagents for apoptosis and cell surface marker assays. The slide-based high content analysis (HCA) and screening tool enables real-time, non-intrusive analysis of adhering or non-adhering living cells within heterogeneous populations. Scientists will be able to study individual cells in micron-sized wells with an assigned location using a standard laboratory microscope.

The disposable, sterile microscope slides have an embedded transparent array of picowells. This enables multiple functional assays on living cells followed by post-fixation studies on the same cells. The processes of staining, rinsing, and perfusions do not displace the cells. Image analysis software designates an address to each cell. Product support will be supplied by the research laboratory staff at Nalge Nunc International.

Nalge Nunc International manufactures, designs, and develops products for use in labware, packaging, biotech, environmental, and life science applications.



Related Links:
Nalge Nunc International
Molecular Cytomics

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.